Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
Recruiting
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Other: Asciminib
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT06092879
- Locations
- 🇫🇷
Novartis Investigative Site, Vesoul, France
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: ribociclib
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06075758
- Locations
- 🇦🇪
Novartis Investigative Site, Al Ain Abu Dhabi, United Arab Emirates
A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China
Recruiting
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Other: Xolair
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT06053801
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
Phase 3
Recruiting
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 468
- Registration Number
- NCT06042478
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06031844
- Locations
- 🇺🇸
Valley Clinical Trials, Northridge, California, United States
🇺🇸University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸Monument Health Clinical Research, Rapid City, South Dakota, United States
Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2089
- Registration Number
- NCT06021366
- Locations
- 🇵🇹
Novartis, Porto Salvo, Portugal
A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma
Recruiting
- Conditions
- Spinal Muscular Atrophies
- Interventions
- Other: Onasemnogene Abeparvovec
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06019637
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US
Completed
- Conditions
- Dry Eye Disease
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 946
- Registration Number
- NCT06018571
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT06006559
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care
Completed
- Conditions
- Heart Failure
- Interventions
- Other: Heart Failure medications
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 899
- Registration Number
- NCT06004453
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
© Copyright 2025. All Rights Reserved by MedPath